Apellis Presents P-III Studies (OAKS) and (DERBY) Results of Syfovre (pegcetacoplan) in Patients with Geographic Atrophy at ARVO 2023
Shots:
- The post hoc analysis results from the 24mos. P-III studies (OAKS) and (DERBY) evaluating Syfovre in 637 & 621 patients with GA secondary to AMD
- The results showed a visual function & QoL benefits with extrafoveal lesions, reduction in the loss of both photoreceptor & RPE cells over sham in treatment with every other month (46% & 46%) and (20% & 21%) in both studies and in monthly (53% & 47%) and (22% & 27%), respectively. The results were consistently comparing Syfovre-treated study eyes to the untreated fellow eyes
- Five regulatory agencies globally are currently reviewing the marketing applications; a decision in the EU is anticipated in early 2024 & decisions in Canada, Australia, Switzerland & the UK are anticipated in H1’24
Ref: GlobeNewswire | Image: Apellis
Related News:- Apellis’ Syfovre Receives the US FDA’s Approval as the First Treatment for Geographic Atrophy
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
